Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franz Oesch

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Pharmacogenetics and Genomics|October 19, 2006
Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicityHelena Carmo, Marc Brulport, Matthias Hermes, et al.
Drug Metabolism Reviews|September 10, 2003
New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation proceduresRolf Gebhardt, Jan G Hengstler, Dieter Müller, et al.
Cancer Research|November 13, 2003
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remissionIlka B Schiffer, Susanne Gebhard, Carolin K Heimerdinger, et al.
Archives of Toxicology|October 21, 2017
Adverse outcome pathways: opportunities, limitations and open questionsMarcel Leist, Ahmed Ghallab, Rabea Graepel, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Pharmacogenetics and Genomics|October 19, 2006
Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicityHelena Carmo, Marc Brulport, Matthias Hermes, et al.
Drug Metabolism Reviews|September 10, 2003
New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation proceduresRolf Gebhardt, Jan G Hengstler, Dieter Müller, et al.
Cancer Research|November 13, 2003
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remissionIlka B Schiffer, Susanne Gebhard, Carolin K Heimerdinger, et al.
Archives of Toxicology|October 21, 2017
Adverse outcome pathways: opportunities, limitations and open questionsMarcel Leist, Ahmed Ghallab, Rabea Graepel, et al.
Pageof 7